

COMPANY PRESENTATION

Attached is a presentation on the Company's activities. The presentation will also be available to shareholders on the OBJ web site.

About OBJ:

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.

OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies:

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward-looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

For more information:

OBJ Ltd:

Mr Glyn Denison
Director

Telephone +618 9443 3011
Email info@obj.com.au
Web www.obj.com.au



OBJ Limited

Leaders in enhanced skin-penetration
solutions for the global

**Pharmaceutical, Cosmetic, Skincare,
Oral health and Consumer
Healthcare Industries**

OBJ
LIMITED

Disclaimer

This Presentation has been prepared by OBJ Limited (ABN 72 056 482 636) (OBJ or the Company). This Presentation contains summary information about OBJ and its activities current as at the date of this Presentation. The information in this Presentation is of general background and does not purport to be complete or to comprise all the information that a shareholder or potential investor in OBJ may require in order to determine whether to deal in OBJ shares. It should be read in conjunction with OBJ's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), which are available at www.asx.com.au. This document is not a prospectus or a product disclosure statement under the Corporations Act (Cth) 2001 (Corporations Act) and has not been lodged with the Australian Securities and Investments Commission (ASIC).

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This Presentation contains certain "forward-looking statements". The words "expect", "should", "could", "may", "will", "predict", "plan", "scenario", "forecasts", "anticipates", "outlook" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Such forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with the Company and the industry (including those set out below) which may affect the accuracy of the forward-looking statements. The Company does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this presentation, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

This document may not be released or distributed in the United States. This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. Securities in the Company have not been, and will not be, registered under the U.S. Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States unless the securities are registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration.

To the maximum extent permitted by law, OBJ and its respective advisers and affiliates, directors, officers and employees make no representation or warranty, express or implied, as to the accuracy, reliability or completeness of information in the Presentation.

Key Facts

KEY STATISTICS (16.05.2014)

ASX Code	OBJ
Current Share Price	\$0.076
52 Week High	\$0.115
52 Week Low	\$0.01
Shares on Issue	1,458m
Market Capitalisation	\$111m
Net Cash (30/3/2014)	~\$4.6m
Options	166m OBJOA (ex 1 cent, exp 31/12/14)
Cash Burn per month	~\$120k

SHAREHOLDER BREAKDOWN

Top 5 Shareholders	7%
Top 20 Shareholders (inc top 5)	21%
Management	6%

12 MONTH SHARE PRICE PERFORMANCE



Company Board & Management

- **Glyn Denison – Non Exec Director & Chairman**

- Over 30 years experience in international business development including 16 years in technology intensive industries in Europe, China and South East Asia and Australia.
- Extensive managerial experience in high technology companies.

- **Jeff Edwards – Founder, Technical Director & Director of Operations**

- Responsible for scientific and technology development & oversees/assists Partner trials.
- Also responsible for client support and works closely with the Company's International Partnering and Executive team.

- **Dr Christopher Quirk – Medical Director**

- 25 years in both lecturing and research at the University of Western Australia.
- Experience in the public and private sector as a consultant dermatologist.
- Fellow of the Australasian College of Dermatologists, Member of the American Academy of Dermatology.

- **Dr Kevin Hammond - International Partnering Manager**

- Leads OBJ's international partnering activities and is the primary liaison for clients in Europe and USA.
- Responsible for managing the partnering, licensing
- Reckitt Benckiser, Unilever, PZ Cussons, CB Fleet (US) and GlaxoSmithKline (UK).

- **Dr Matt McIldowie – Research Manager**

- Responsible for partnering programs at the technical and study level.
- Extensive experience in diverse fields such as medicinal/pharmaceutical chemistry, biological chemistry, industrial processes and materials.


Core Technologies

5

- Science based on physics rather than chemistry
- Enhanced performance of consumer products without reformulation
- Increased speed and effectiveness for “through the skin” drugs
- Greater penetration and outcomes for cosmetic & consumer products
- Broad Patent portfolio of 20 filings
- 5 Technologies with the OBJ Platform
 - Micro-array film
 - Field in Motion
 - EPPS
 - Dermaportation
 - E-skin



Product performance enhancement



The addition of just a few cents in manufacturing cost provides a substantial increase in consumer relevant performance without any of the usual costs of reformulations and delivers a clear marketable advantage over competitors.

*OBJ internal *in vivo* study

OBJ's Business Strategy


For sectors with established brand leaders and global distribution



Partnering with
licensing & royalties

- Pharmaceuticals
- Oral healthcare
- Colour Cosmetics
- Consumer Skin Care
- Analgesics

For new and emerging sectors with less established brand leaders



Develop to high value-add
for branding and supply

- BodyGuard
- HotDot
- Measured dose applicators

Key Business Partners

Procter & Gamble



8

- Wide ranging Product Development Agreement (PDA) signed in April 2014
- First Licensing Agreement signed for first product to market
- Two additional major product developments agreed and budgeted
- Five additional new product developments under final planning
- P&G NBG charged with introducing technology across all brands
- Commercial
 - P&G annual turnover of \$84 billion, 50 of the world's leading brands including Olay, Head & Shoulders, Braun, Gillette, SK-II

Key Business Partners

Procter & Gamble



9

- Agreements covering 7 of P&G key product categories
- License fees & Royalties based upon end product value.
- Terms for all product licenses agreed
- P&G to pay all OBJ's development program costs.
- Guaranteed minimum investment levels for life of agreements

Key Business Partners

GSK – Oral Healthcare

- 6 year continuous collaboration
- Successful multiple pre-clinical programs completed
- First in-mouth human efficacy study completed
- Larger consumer study planned
- Progressing through ethics committee approval prior to commencement of human clinical trials.
- Successful multiple pre-clinical programs completed
 - Enhanced fluoride delivery
 - Dentine sensitivity (Sensodyne)
 - Re-mineralisation (rehardening)



Key Business Partners

GlaxoSmithKline -Analgesics

- Relationship commenced in 2012
- Focused on enhanced topical delivery of GSK proprietary analgesic formulations
- Pain Management Group recently moved to Singapore
- New emphasis on natural ingredients
- Phase 1 program completed in 2013
- Phase 2 program completed in early 2014
- Phase 3 program being planned



Key Business Partners

COTY – Skincare, Cosmetic & Fragrances

COTY are the world's largest Fragrance company
World's fastest growing prestige skincare company
Annual turnover in excess of \$9 billion

Initial POP studies completed in 2013
Human Clinical trial completed in late 2013

Development Agreement extended for product development and pre-launch claims support

Coty pays all development costs, consumer testing & evaluation.

License agreements expected to follow consumer acceptance testing.

philosophy
Calvin Klein
fragrances

Chloé

RIMMEL
LONDON

Sally Hansen
#1 USA NAIL EXPERT

O·P·I

adidas

BodyGuard

A new product platform designed to deliver

key joint lubricating and energy absorbing molecules

directly into the joint to replace and support those degraded by age, exercise or injury

A new category of consumer focused products designed to alter joint aging, not just treat the resulting pain.



BodyGuard –

Keeps you in the game

Development Status

- First Clinical Trial completed
- Overall performance improvement > 14% after 2 weeks daily use
- Proprietary “Lubricen” formulation
TGA Listed a medicine
- Global regulatory strategy completed
- Larger clinical trial being planned
through AIS, SMA or JMU (UK).



BodyGuard's three product platform

ELITE SPORTS



Durable device with multiple insertable formulation pods

LIFESTYLERS



Low cost patch for maintaining joint health

VIRTUAL BATCH



Virtual Patch formulation for gym, sports and OA

Thank you

Corporate Offices

Glyn Denison
Director
Level 1, 284 Oxford Street
Leederville 6007
Perth, Western Australia
gdenison@obj.com.au

Research and Develop Centre

Jeffrey Edwards
Technical Director
Level 1, 284 Oxford Street
Leederville 6007
Perth, Western Australia
jedwards@obj.com.au

International Partnering Office

Dr Kevin Hammond
International Partnering
Manager
1 Porto Hey Road
Irby, Wirral
United Kingdom

Own Products Development

George Tsadilas
Product Development Manager
284 Oxford Street
Leederville 6007
Perth, Western Australia

